GCP
PHAS

GSA Capital Partners’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

GSA Capital Partners’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-186,031
Closed -$692K – 1897
2021
Q2 		$692K Sell
186,031
-24,625
-12% -$82K 0.08% 429
2021
Q1 		$729K Buy
210,656
+70,315
+50% +$285K 0.12% 201
2020
Q4 		$472K Sell
140,341
-13,975
-9% -$50K 0.08% 456
2020
Q3 		$542K Buy
+154,316
New +$622K 0.09% 345

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

GSA Capital Partners's PHAS Position: Q3 2021 in Review

GSA Capital Partners sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2021, closing a stake of 186,031 shares — an estimated $692K sold.

GSA Capital Partners first reported a position in PHAS in Q3 2020 and held it in 4 quarters. The position peaked at $729K in Q1 2021. 61 funds tracked by Wall St. Rank hold PHAS as of Q3 2021.

  • GSA Capital Partners reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 186,031 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $692K.
  • GSA Capital Partners first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • GSA Capital Partners's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $729K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.